Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CAR-NK + CAR-T
- Development stage
- Preclinical
- Lead developer
- Tasrif Pharmaceutical
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CAR-NK + CAR-T (also known as Anti-CD155 Cell Therapy) is a preclinical-stage cell therapy being developed by Tasrif Pharmaceutical. It is part of Tasrif's broader CD155-targeting platform, which leverages the company's patented humanized anti-CD155 antibodies (centered on the lead molecule TSRF-786C) to engineer next-generation cancer immunotherapy modalities. The therapy targets CD155 (Poliovirus Receptor, PVR), which is overexpressed on many malignancies, including blood tumors and solid tumors. The modality is a CD155-directed chimeric antigen receptor (CAR) immune-cell therapy combining both CAR-NK (natural killer cell) and CAR-T (T cell) approaches. It is currently in the discovery/preclinical stage of development.
- Other names
- Anti-CD155 Cell TherapyAnti-CD-155 Cell TherapyAnti-CD 155 Cell TherapyTSRF CAR-NK and CAR-T
Beyond the preview
Go deeper on CAR-NK + CAR-T.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CAR-NK + CAR-T.